Aspirin plus rivaroxaban efficacy and safety in embolic stroke of undetermined source: A randomized, placebo-controlled, outcome assessor-blind, feasibility study.

Introduction: The high prevalence of patients with embolic stroke of undetermined source (ESUS), the considerable risk of ischemic stroke, and the need for novel antithrombotic strategies highlight ESUS as an important priority in stroke research in the coming years. This study is designed to investigate the effectiveness and safety of rivaroxaban along with aspirin in reducing stroke recurrence in patients with ESUS.

Materials And Methods: The present study is a parallel-group, placebo-controlled, randomized, outcome-assessor blind, on patients in whom ESUS has recently (7-60 days) identified and had one risk factor of a potential embolic source.